PHPT1 acts as an inhibitor in high-altitude pulmonary hypertension via negative TRPV5 signaling regulation.

BACKGROUND

Low barometric pressure hypoxia at high altitudes triggers vascular remodeling, resulting in high-altitude pulmonary hypertension (HAPH). The key step is the transformation of pulmonary artery smooth muscle cells (PASMCs) from a contractile to synthetic phenotype. Protein kinases and phosphatases contribute to phenotype transformation by altering phosphorylated protein expression.

OBJECTIVES

In this study, we aimed to investigate the role of phosphohistidine phosphatase 1 (PHPT1) in PASMC transformation and its regulatory pathway in HAPH.

METHODS

An HAPH model was constructed in wild-type, PHPT1-/-, and PHPT1+/+ rats by placing them in a hypobaric chamber. Evaluations included hemodynamic measurements, echocardiography, histopathological analysis, and various cellular assays. RNA-seq and western blotting were used to identify intervention targets, and co-immunoprecipitation was used to determine the interaction between PHPT1 and TRPV5.

RESULTS

PHPT1 protein expression was downregulated in HAPH, and its knockdown impaired cardiopulmonary functions, including elevated mean pulmonary artery pressure (mPAP), right ventricular systolic pressure (RVSP), and increased right ventricular thickness, and enhanced PASMC proliferation and migration. PHPT1 directly interacted with TRPV5 phosphorylation sites, whereas Asp30Ala/Arg157Ala functioned to prevent this interaction. PHPT1 overexpression protected against cardiopulmonary damage, reducing mPAP, RVSP, the D/W ratio, and MWT%. Additionally, PHPT1 overexpression mitigated PASMC proliferation and migration, resulting in restored TRPV5, p-Akt, p-SMAD2/3, and p-TGF-β expression under hypoxic conditions.

CONCLUSIONS

These findings underscore that PHPT1 inhibits PASMC proliferation and migration through TRPV5 signaling, thereby reducing mPAP and improving right ventricular function in HAPH. Therefore, PHPT1 targeting could potentially contribute to the development of novel therapeutic approaches for treating HAPH.